Literature DB >> 8455666

Comparison of cardiac pacing with drug therapy in the treatment of neurocardiogenic (vasovagal) syncope with bradycardia or asystole.

J S Sra1, M R Jazayeri, B Avitall, A Dhala, S Deshpande, Z Blanck, M Akhtar.   

Abstract

BACKGROUND: The efficacy of permanent cardiac pacing in patients with neurocardiogenic (or vasovagal) syncope associated with bradycardia or asystole is not clear. We compared the efficacy of cardiac pacing with that of oral drug therapy in the prevention of hypotension and syncope during head-up tilt testing.
METHODS: Among 70 patients with a history of syncope in whom hypotension and syncope could be provoked during head-up tilt testing, 22 had bradycardia (a heart rate < 60 beats per minute, with a decline in the rate by at least 20 beats per minute) or asystole along with hypotension during testing. There were 9 men and 13 women, with a mean (+/- SD) age of 41 +/- 17 years. Head-up tilt testing was repeated during atrioventricular sequential pacing (in 20 patients with sinus rhythm) or ventricular pacing (in 2 patients with atrial fibrillation). Regardless of the results obtained during artificial pacing, all the patients subsequently had upright-tilt testing repeated during therapy with oral metoprolol, theophylline, or disopyramide.
RESULTS: During the initial tilt test, 6 patients had asystole and 16 had bradycardia along with hypotension. Despite artificial pacing, the mean arterial pressure during head-up tilt testing still fell significantly, from 97 +/- 19 to 57 +/- 19 mm Hg (P < 0.001); 5 patients had syncope, and 15 had presyncope. By contrast, 19 patients who later received only medical therapy (metoprolol in 10, theophylline in 3, and disopyramide in 6), 2 patients who received both metoprolol and atrioventricular sequential pacing, and 1 patient who received only atrioventricular sequential pacing had negative head-up tilt tests. After a median follow-up of 16 months, 18 of the 19 patients who were treated with drugs alone (94 percent) remained free of recurrent syncope or presyncope, whereas the patient treated only with permanent dual-chamber pacemaker had recurrent syncope.
CONCLUSIONS: In patients with neurocardiogenic syncope associated with bradycardia or asystole, drug therapy is often effective in preventing syncope, whereas artificial pacing is not.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8455666     DOI: 10.1056/NEJM199304153281504

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  36 in total

1.  Treatment of vasovagal syncope: pacemaker or crossing legs?

Authors:  N van Dijk; M P Harms; M Linzer; W Wieling
Journal:  Clin Auton Res       Date:  2000-12       Impact factor: 4.435

Review 2.  Heart rate and orthostatic stress.

Authors:  R Hainsworth
Journal:  Clin Auton Res       Date:  2000-12       Impact factor: 4.435

Review 3.  Can cardiac pacing prevent neurocardiogenic syncope?

Authors:  A K Gupta; A Maheshwari; R K Thakur; C P Shah; Y Y Lokhandwala
Journal:  J Interv Card Electrophysiol       Date:  2001-12       Impact factor: 1.900

Review 4.  Permanent pacing: new indications.

Authors:  M R Gold
Journal:  Heart       Date:  2001-09       Impact factor: 5.994

5.  Vasodepressor Syncope.

Authors: 
Journal:  Curr Treat Options Cardiovasc Med       Date:  2000-08

Review 6.  Has cardiac pacing a role in vasovagal syncope?

Authors:  Richard Sutton
Journal:  J Interv Card Electrophysiol       Date:  2003-10       Impact factor: 1.900

Review 7.  Permanent cardiac pacing as primary therapy for neurocardiogenic (reflex) syncope.

Authors:  Daniel J Kosinski; Blair P Grubb; Douglas A Wolfe
Journal:  Clin Auton Res       Date:  2004-10       Impact factor: 4.435

8.  [Not Available].

Authors:  K Wittig; C Meyer; A Neugebauer; D Pfeiffer
Journal:  Herzschrittmacherther Elektrophysiol       Date:  1998-02

9.  [A patient with syncope].

Authors:  Helene Höhler
Journal:  Med Klin (Munich)       Date:  2009-10-15

Review 10.  Syncope: investigation and treatment.

Authors:  Satish R Raj; Robert S Sheldon
Journal:  Curr Cardiol Rep       Date:  2002-09       Impact factor: 2.931

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.